Possible Cure for HIV/AIDS Discovered

Prof. Isaiah Ibeh is the current Dean, School of Basic Medical Sciences, University of Benin located in Edo state Nigeria. Prof Ibeh on Tuesday January 8th (i.e. yesterday) announced that a new drug that can cure HIV and AIDS has been developed by his team.

The Prof told the News Agency of Nigeria in Benin, the Edo State capital, that research for the drug started since 2010 and culminated in the development of a product - Deconcotion X (DX)–Liquid or Bioclean 11 - for the cure of HIV/AIDS. He further added that the new drug had undergone “a series of successful tests.”

According to reports by NAN, Prof Ibeh is quoted thus:

“We are at the threshold of making history, in the sense that we seem to have with us something that will permanently take care of what over time seems to have defied all solutions.

“We are talking about the latest discovery of an oral drug made from plants extraction in Nigeria for the possible cure for the pandemic, HIV and AIDS virus.’’

“The existing retroviral drugs are intervention drugs for the management of AIDS but our new discovery is a possible cure. We have tried to look at the product first; its toxicological analysis and discovered that it has a large safety margin.

“This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure.

“It also helped us to know the quantity we can conveniently give to animals and will feel secure that nothing untoward will happen.

“We have also done the bacteriological analysis on it, after which we looked at its effect on the virus and the result was quite revealing and refreshing.’’

NAN reports that the University professor confirmed that the drug had undergone series of medical testing both in Nigeria and the USA; and noted to have performed well on HIV patients with evidence of total restoration of damaged tissues.

“The result showed an increase in the body weight of the individual administered with DX.

“The body weight was statistically significant when compared with the control group.’’

He notes that further tests are being conducted to determine “at what point will a patient become negative after being administered the drug?”

“This verification is necessary because it is what is used to measure whether infection is still there or not. So we need to know the siro-convention time.

“But preliminary results showed that of the five latest patients orally administered with the drugs, our findings is that up to seven months three of them were siro negative while two were still faintly positive.’’